De Burlo Group’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

De Burlo Group’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-200	Closed	-$1.34K	–	192
2022 Q3	$1.34K	Buy	+200	New	+$1.21K	﹤0.01%	183
2022 Q2	–	Sell	-200	Closed	-$674	–	205
2022 Q1	$674	Buy	+200	New	+$634	﹤0.01%	168

Other funds holding CNCE

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

De Burlo Group's CNCE Position: Q4 2022 in Review

De Burlo Group sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2022, closing a stake of 200 shares — an estimated $1.34K sold.

De Burlo Group first reported a position in CNCE in Q1 2022 and held it in 2 quarters. The position peaked at $1.34K in Q3 2022. 85 funds tracked by Wall St. Rank hold CNCE as of Q4 2022.

De Burlo Group reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
De Burlo Group sold 200 Concert Pharmaceuticals, Inc. shares in Q4 2022, an estimated $1.34K.
De Burlo Group first reported a position in Concert Pharmaceuticals, Inc. in Q1 2022 and held it in 2 quarters.
De Burlo Group's Concert Pharmaceuticals, Inc. position peaked at $1.34K in Q3 2022.
85 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2022.

Based on De Burlo Group's 13F filing for Q4 2022, filed 14 Feb 2023.